Shots:
- Roche has reported P-III (IMforte) trial data of Tecentriq + lurbinectedin as 1L maintenance therapy for ES-SCLC pts (≥18yrs)
- Trial assessed the regimen vs Tecentriq monotx. in ES-SCLC pts, where 660 pts received induction therapy with Tecentriq + CT (4 x 21-day cycles) & 483 pts without progression were then randomized to maintenance with either the regimen or monotx. until progression or unacceptable toxicity
- Trial showed improved PFS (1EP) by 46% & a 27% decrease in death risk, with mOS of 13.2 vs 10.6mos. & mPFS of 5.4 vs 2.1mos. from randomization; data was shared at ASCO 2025 & published in The Lancet
Ref: Roche | Image: Roche | Press Release
Related News:- Roche’s Itovebi Regimen Secures the CHMP’s Positive Opinion for PIK3CA-mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
